43 participants
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-08
- Start Date:
- 2024-08-20
- Completion:
- 2030-09-02
Conditions
- Multiple Myeloma
Interventions
- DRUG
No Results Yet